​

Biogen (BIIB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BIIB Stock Forecast

Biogen (BIIB) stock forecast, based on 47 Wall Street analysts, predicts a 12-month average price target of $206.76, with a high of $250.00 and a low of $143.00. This represents a 11.82% increase from the last price of $184.90.

$100 $140 $180 $220 $260 $300 High: $250 Avg: $206.76 Low: $143 Last Closed Price: $184.9

BIIB Stock Rating

Biogen stock's rating consensus is Buy, based on 47 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 25 Buy (53.19%), 21 Hold (44.68%), 1 Sell (2.13%), and 0 Strong Sell (0.00%).

Buy
Total 47 1 21 25 Strong Sell Sell Hold Buy Strong Buy

BIIB Price Target Upside V Benchmarks

TypeNameUpside
StockBiogen11.82%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks1.85%

Price Target Trends

1M3M12M
# Anlaysts12032
Avg Price Target$185.00$208.20$195.19
Last Closing Price$184.90$184.90$184.90
Upside/Downside0.05%12.60%5.57%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26114201-36
Feb, 26214181-35
Jan, 26214181-35
Dec, 2521419--35
Nov, 2531319--35
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 19, 2026Emily FieldBarclays$185.00$192.08-3.69%0.05%
Feb 11, 2026Mizuho Securities$236.00$188.9924.87%27.64%
Feb 10, 2026Laura ChicoWedbush$187.00$192.72-2.97%1.14%
Feb 09, 2026Wolfe Research$231.00$196.0017.86%24.93%
Feb 09, 2026RBC Capital$233.00$195.9318.92%26.01%
Feb 09, 2026Danielle BrillTruist Financial$193.00$201.18-4.07%4.38%
Feb 09, 2026Canaccord Genuity$230.00$201.1814.33%24.39%
Feb 09, 2026Piper Sandler$177.00$201.18-12.02%-4.27%
Feb 09, 2026Yatin SunejaGuggenheim$246.00$201.1822.28%33.04%
Feb 09, 2026William PickeringTudor Pickering$201.00$201.18-0.09%8.71%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 10, 2026WedbushNeutralNeutralhold
Feb 09, 2026Goldman SachsBuyBuyhold
Feb 09, 2026RBC CapitalOutperformOutperformhold
Feb 09, 2026Cowen & Co.BuyBuyhold
Feb 09, 2026Piper SandlerNeutralNeutralhold
Feb 09, 2026GuggenheimBuyBuyhold
Feb 09, 2026BernsteinMarket PerformMarket Performhold
Feb 09, 2026H.C. WainwrightBuyBuyhold
Feb 06, 2026BMO CapitalMarket PerformMarket Performhold
Jan 30, 2026OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$5 $10 $15 $20 $25 $30 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.44$20.97$8.02$11.20$8.85---
Avg Forecast$19.19$17.11$14.99$16.42$16.48$17.37$18.95$20.72
High Forecast$20.57$18.68$15.57$17.18$20.03$25.69$26.87$23.62
Low Forecast$18.00$15.76$14.74$16.13$14.45$13.83$15.13$18.61
Surprise %-45.60%22.56%-46.50%-31.79%-46.30%---

Revenue Forecast

$9B $9B $10B $10B $11B $12B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.98B$10.17B$9.84B$9.68B$9.81B---
Avg Forecast$10.87B$10.07B$9.93B$9.63B$9.43B$9.56B$9.92B$10.14B
High Forecast$11.47B$10.78B$10.08B$9.74B$10.42B$9.57B$9.94B$11.23B
Low Forecast$10.35B$9.46B$9.78B$9.55B$8.69B$9.56B$9.89B$9.35B
Surprise %1.01%1.00%-0.93%0.43%4.04%---

Net Income Forecast

$500M $1B $2B $3B $3B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.56B$3.05B$1.16B$1.63B$1.29B---
Avg Forecast$1.37B$1.82B$1.16B$2.42B$2.51B$2.37B$2.56B$3.02B
High Forecast$1.64B$2.18B$1.39B$2.50B$2.92B$3.74B$3.91B$3.44B
Low Forecast$1.09B$1.46B$928.88M$2.35B$2.10B$2.01B$2.20B$2.71B
Surprise %13.84%67.40%--32.69%-48.48%---

BIIB Forecast FAQ

Is Biogen stock a buy?

Biogen stock has a consensus rating of Buy, based on 47 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 25 Buy, 21 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Biogen is a favorable investment for most analysts.

What is Biogen's price target?

Biogen's price target, set by 47 Wall Street analysts, averages $206.76 over the next 12 months. The price target range spans from $143 at the low end to $250 at the high end, suggesting a potential 11.82% change from the previous closing price of $184.9.

How does Biogen stock forecast compare to its benchmarks?

Biogen's stock forecast shows a 11.82% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the drug manufacturers - general stocks industry (1.85%).

What is the breakdown of analyst ratings for Biogen over the past three months?

  • March 2026: 2.78% Strong Buy, 38.89% Buy, 55.56% Hold, 2.78% Sell, 0% Strong Sell.
  • February 2026: 5.71% Strong Buy, 40.00% Buy, 51.43% Hold, 2.86% Sell, 0% Strong Sell.
  • January 2026: 5.71% Strong Buy, 40.00% Buy, 51.43% Hold, 2.86% Sell, 0% Strong Sell.

What is Biogen’s EPS forecast?

Biogen's average annual EPS forecast for its fiscal year ending in December 2026 is $17.37, marking a 96.27% increase from the reported $8.85 in 2025. Estimates for the following years are $18.95 in 2027, and $20.72 in 2028.

What is Biogen’s revenue forecast?

Biogen's average annual revenue forecast for its fiscal year ending in December 2026 is $9.56B, reflecting a -2.51% decrease from the reported $9.81B in 2025. The forecast for 2027 is $9.92B, and $10.14B for 2028.

What is Biogen’s net income forecast?

Biogen's net income forecast for the fiscal year ending in December 2026 stands at $2.37B, representing an 83.24% increase from the reported $1.29B in 2025. Projections indicate $2.56B in 2027, and $3.02B in 2028.